A Phase 2 interventional study of DaxibotulinumtoxinA for injection in Upper Facial Lines (Glabellar Lines, Forehead Lines, & Lateral Canthal Lines), sponsored by Revance Therapeutics, Inc.. Completed at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-27.
Sponsored by Revance Therapeutics, Inc. (part of Revance) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of DaxibotulinumtoxinA for injection (DAXI for injection) in the treatment of Glabellar Lines (GL), Dynamic Forehead Lines (FHL), and Lateral Canthal Lines(LCL)
Revance Therapeutics, Inc. is the lead sponsor of 29 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
First submitted before Revance Therapeutics, Inc. became part of Revance.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DaxibotulinumtoxinA for injection for the treatment of moderate to severe Glabellar Lines (GL), Forehead Lines (FHL), \& Lateral Canthal Lines (LCL)
Drug: DaxibotulinumtoxinA for injection
Intramuscular injection
Percentage of Participants With None or Mild in GL Severity at Maximum Frown
The percentage of subjects achieving a score of 0 (none) or 1 (mild) in GL severity at maximum contraction (maximum frown) at Week 4 as assessed by the IGA-FWS
Time frame: Week 4
Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation
The percentage of subjects achieving a score of 0 (none) or 1 (mild) in FHL severity at maximum contraction (maximum eyebrow elevation) at Week 4 as assessed by the IGA-FHWS
Time frame: Week 4
Percentage of Participants With None or Mild in LCL Severity at Maximum Smile Effort
The percentage of subjects achieving a score of 0 (none) or 1 (mild) in LCL severity at maximum contraction (maximum smile effort) at Week 4 as assessed by the IGA-LCWS
Time frame: Week 4
| Milestone | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Started | 48 |
| Completed | 45 |
| Not completed | 3 |
The percentage of subjects achieving a score of 0 (none) or 1 (mild) in GL severity at maximum contraction (maximum frown) at Week 4 as assessed by the IGA-FWS
| Participants | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Percentage of Participants With None or Mild in GL Severity at Maximum Frown | 46 |
The percentage of subjects achieving a score of 0 (none) or 1 (mild) in FHL severity at maximum contraction (maximum eyebrow elevation) at Week 4 as assessed by the IGA-FHWS
| Participants | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation | 46 |
The percentage of subjects achieving a score of 0 (none) or 1 (mild) in LCL severity at maximum contraction (maximum smile effort) at Week 4 as assessed by the IGA-LCWS
| Participants | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Percentage of Participants With None or Mild in LCL Severity at Maximum Smile Effort | 44 |
Collected over The adverse events were collected throughout the entire study, up to 36 weeks after treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| DAXI 40 U GL / 32 U FHL / 48 U LCL | 0/48 (0%) | 1/48 (2.1%) | 3/48 (6.3%) |
| Event | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| COVID-19 pneumoniaInfections and infestations | 1/48 |
| Event | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Injection site erythemaGeneral disorders | 3/48 |
Safety Population
| Age, Continuous(years) | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Mean | 48.9 (23 to 84) |
| Sex: Female, Male(Participants) | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Female | 40 |
| Male | 8 |
| Race/Ethnicity, Customized(Participants) | DAXI 40 U GL / 32 U FHL / 48 U LCL |
|---|---|
| Race — White | 44 |
| Race — Black/African American | 3 |
| Race — Other | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2019 to primary completion in Nov 2020, 10 months.
Results were first posted in Jun 2023, 2 years 7 months after primary completion. A results delay was requested in Feb 2021.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Botulinum toxin type A